Follow Us:
Clinical Advances: Individualizing Treatment for Chronic Lymphocytic Leukemia
Hematology-Oncology
Curriculum:
Clinical Advances: Individualizing Treatment for Chronic Lymphocytic Leukemia
Clinical Advances: Individualizing Treatment for Chronic Lymphocytic Leukemia
Credits:
1.0 AMA PRA Category 1 Credit(s) ™ 1.0 AANP Contact Hours .75 Pharmacology
1.0 AMA PRA Category 1 Credit(s) ™ 1.0 AANP Contact Hours .75 Pharmacology
Launch Date:
August 08, 2019
August 08, 2019
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Oncology, Hematology, and other clinicians that care for patients with CLL.
Relevant Terms:
Noah Kornblum, MD
Assistant Professor, Department of Medicine (Oncology)
Bone Marrow Transplant/Heme Malignancy
Montefiore Einstein Center for Cancer Care
Bronx, NY
Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd
Chief Medical Officer and Executive Vice President
CLL Society
Claremont, CA
Rasim A. Gucalp, MD, FACP
Course Director and Moderator
Professor, Department of Medicine (Oncology)
Albert Einstein College of Medicine
Montefiore Medical Center
Director, Hematology/Oncology Fellowship Program
Bronx, NY
| 1. | Use patient’s age, prognostic markers, comorbidities and patient’s preferences when individualizing CLL management | 2. | Utilize new and emerging therapies as well as chemo-immunotherapy for the appropriate patients with CLL |
| 3. | Understand the importance of degree of response to therapy, including U-MRD (undetectable Minimal Residual Disease), in managing care | 4. | Recognize and manage the common complications related to the medications used to treat CLL |
| 1. | Use patient’s age, prognostic markers, comorbidities and patient’s preferences when individualizing CLL management |
| 2. | Utilize new and emerging therapies as well as chemo-immunotherapy for the appropriate patients with CLL |
| 3. | Understand the importance of degree of response to therapy, including U-MRD (undetectable Minimal Residual Disease), in managing care |
| 4. | Recognize and manage the common complications related to the medications used to treat CLL |
Program Overview:
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries. In 2018, there will be an estimated 20,940 new cases of CLL diagnosed and an estimated 4,510 deaths. CLL is a chronic and generally incurable disease with the average patient receiving multiple lines of therapy throughout their disease course. The treatment goal of CLL is long-term remission and the choice of treatment depends on stage, risk status, and the patient’s overall health. Achieving long-term remission typically requires combination of chemotherapy plus targeted therapies, and stem cell transplant or clinical trials for select high-risk recurrence patients.
Fortunately, the treatment of CLL is one of the most active areas of recent clinical research. There is not one standardized approach for treating patients with CLL.
This activity will examine real-world evidence of treatment practice patterns, and patient outcomes will shed significant light on how hematologists can best personalize treatment to maximize overall survival and patient quality of life.
This webcast was recorded live at the Conversations in Oncology Live Virtual Symposium 2019 and is being used with the permission of the presenters.
ACCME Accreditation Statement:
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ACCME Designation Statement:
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP Accreditation Statement:
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.75 pharmacology hours.
Support Acknowledgement:
This educational activity is supported by an educational grant from Pharmacyclics, LLC.
Course Director and Moderator:
Rasim A. Gucalp, MD, FACP
Professor, Department of Medicine (Oncology)
Albert Einstein College of Medicine
Montefiore Medical Center
Director, Hematology/Oncology Fellowship Program
Bronx, NY
CME Reviewer:
Victor Hatcher, PhD
Associate Dean for Continuing Medical Education
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY
Medical Writer:
Josh Kilbridge, Medical Writer, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Disclosures:
Dr. Gucalp has no relevant conflicts of interest with any ACCME-defined commercial interest.
Dr. Koffman has received a consulting fee from Janssen, Novartis, and Verastem Oncology. He also has ownership interest for: Abbvie, AstraZeneza, BeiGene, Bristol-Myers Squibb, Celgene, Gilead Sciences, Inc., Johnson & Johnson, MEI Pharma Inc, Miragen Therapeutics Inc, Portola Pharmaceuticals Inc, Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc, and Verastem Oncology.
Dr. Koffman has indicated that his reported relationships will not impact his ability to present an unbiased presentation.
Dr. Kornblum has no relevant conflicts of interest with any ACCME-defined commercial interest.
Faculty Disclosure Policy:
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities.
The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship with a commercial interest*. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Faculty disclosures are provided below.
*The ACCME defines a commercial interest as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providing clinical service directly to patients to be commercial interests - unless the provider of the clinical service is owned, or controlled by, an ACCME-defined commercial interest.
Planning Committee:
Gregg Sherman, MD, Activity Planning Committee, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Josh Kilbridge, Medical Writer, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Michelle Frisch, MPH, Activity Planning Committe, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Daniela Hiedra, BA, Activity Planning Committee, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Sandy Bihlmeyer, MEd, Activity Planning Committee, has no relevant conflicts of interest with any ACCME-defined commercial interest.
How to claim credit:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Course format/medium: Internet CME Activity
Estimated time to complete activity: 60 minutes
Disclaimer: The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine or the National Association for Continuing Education. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
